Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis

Table 1 Events Prevented and Caused by Antiplatelet Therapy for Every 1000 Patients Treated

Outcome	OR (95% CI)	NNT (95% CI)	ARR (95% CI)^a	CER (%)
Major cardiovascular events	0.85 (0.74,0.94)	44 (26,112)	23 (9,39)	18
Access failure	0.52 (0.31,0.73)	9 (6,16)	116 (61,180)	30
Any bleeding	1.55 (1.25,1.84)	−29 (−62, − 19)	−35 (− 52,-16)	3
Major bleeding	1.33 (1.11,1.59)	− 114 (− 339, − 64)	−9 (− 16, − 3)	6
Minor bleeding	1.66 (1.27,2.05)	−28 (−18, − 68)	−35 (− 55, − 15)	7

ARR Absolute risk reduce, CER Control event risk, CI Confidence interval, eGFR estimated glomerular filtration rate, OR Odds radio, NNT Number needed to be treated, i.e. the number of patients who must be treated to prevent one adverse event
^aValues are absolute risk change (95% CI) of outcome per 1,000 patients treated for a median follow-up duration. Positive values represent the benefits from antiplatelet therapy

ISSN: 1471-2369